Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome (POTS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03930914
Recruitment Status : Not yet recruiting
First Posted : April 29, 2019
Last Update Posted : April 29, 2019
Sponsor:
Collaborator:
Dysautonomia International
Information provided by (Responsible Party):
University of Oklahoma

Brief Summary:

Postural orthostatic tachycardia (POTS) is characterized by abnormalities in the autonomic nervous system in the body. The autonomic nervous system controls and regulates body functions such as heart rate, breathing, digestion, and more.

The investigator has shown that patients with POTS have higher cardiovascular and adrenergic activating autoantibodies (AAb), which likely changes the normal make-up of POTS. There are autoantibodies that have been suggested by a few reports of their presence in POTS, but their role different aspects of POTS is unknown. The study will look at the body's responses in patients with POTS. The crossover study design is to have half of the patients will start with sham followed by active stimulation and half will start by active followed by sham stimulation. It is anticipated that results will provide a potential therapeutic approach based on the understanding of POTS.


Condition or disease Intervention/treatment Phase
Postural Orthostatic Tachycardia Syndrome Device: Transcutaneous Electrical Nerve Stimulation (TENS) Device Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome
Estimated Study Start Date : May 1, 2019
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : January 2022

Arm Intervention/treatment
Active Treatment to Sham
Subjects randomized to the sequence Active Treatment/Sham Treatment arm will be instructed to first use the TENS device as active treatment for the first phase of the study. Next, they will be instructed to use the TENS device as sham treatment for the second phase of the study.
Device: Transcutaneous Electrical Nerve Stimulation (TENS) Device
Daily use of TENS device on tragus or ear lobe, as assigned treatment arm

Sham to Active Treatment
Subjects randomized to the sequence Sham Treatment/Active Treatment arm will be instructed to use the TENS device as sham treatment for the first phase of the study. Next, they will be instructed to use the TENS device as active treatment for the second phase of the study.
Device: Transcutaneous Electrical Nerve Stimulation (TENS) Device
Daily use of TENS device on tragus or ear lobe, as assigned treatment arm




Primary Outcome Measures :
  1. Average change in orthostatic heart rate [ Time Frame: 2 and 4 months ]
    We will measure the average change in heart rate between supine and standing using continuous ECG after two and four months of daily vagal nerve stimulation

  2. Long term effects on M2 muscarinic autoantibody levels [ Time Frame: 2 and 4 months ]
    The average change in M2 muscarinic autoantibody levels measured from blood specimens obtained after two and four months of daily vagal nerve stimulation.

  3. Long term effects on beta 1-adrenergic autoantibody levels [ Time Frame: 2 and 4 months ]
    The average change in beta 1-adrenergic autoantibody levels measured from blood specimens obtained after two and four months of daily vagal nerve stimulation.

  4. Long term effects on alpha 1-adrenergic autoantibody levels [ Time Frame: 2 and 4 months ]
    The average change in alpha 1-adrenergic autoantibody levels measured from blood specimens obtained after two and four months of daily vagal nerve stimulation.

  5. Average change in heart rate variability [ Time Frame: 2 and 4 months ]
    We will measure the average change in heart rate variability based on 5 minute ECG after two and four months of daily vagal nerve stimulation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

-Female or male participants age 18-80

Group 1 (20 participants):

  • A physician-based diagnosis of POTS
  • Participants that have a postural pulse rise of >35 for adolescents and >30 for adults with a Blood Pressure (BP) that does not drop >10/5 mmHg will be qualified. These participants may be on salt and fluid loading.

Group 2 (10 participants):

  • Previously diagnosed with POTS
  • Patients is on Intravenous immunoglobulin (IVIG) infusion but who have an incomplete symptomatic response

Exclusion Criteria:

  • Age < 18 years
  • Sick sinus syndrome, 2nd or 3rd degree Atrioventricular (AV) block, bifascicular block or prolonged 1st degree AV block (PR>300ms).
  • Currently pregnant women or women planning on becoming pregnant ≤ 6 months
  • History of hypotension due to autonomic dysfunction
  • Have a secondary causes of tachycardia (acute anemia or blood loss, drugs, significant cardiomyopathy, diabetes mellitus)
  • Patients with active implants (such as a cardiac pacemaker, or a cochlear implant).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03930914


Contacts
Layout table for location contacts
Contact: Katlyn Beecken, BS 405-271-3490 OSCTR@ouhsc.edu

Locations
Layout table for location information
United States, Oklahoma
University of Oklahoma Health Sciences Center Not yet recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: David Kem, MD         
Sponsors and Collaborators
University of Oklahoma
Dysautonomia International
Investigators
Layout table for investigator information
Principal Investigator: David Kem, MD University of Oklahoma
Principal Investigator: Stavros Stavrakis, MD University of Oklahoma

Layout table for additonal information
Responsible Party: University of Oklahoma
ClinicalTrials.gov Identifier: NCT03930914     History of Changes
Other Study ID Numbers: VNS in POTS
First Posted: April 29, 2019    Key Record Dates
Last Update Posted: April 29, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Postural Orthostatic Tachycardia Syndrome
Tachycardia
Syndrome
Disease
Pathologic Processes
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Cardiac Conduction System Disease
Orthostatic Intolerance
Primary Dysautonomias
Autonomic Nervous System Diseases
Nervous System Diseases